A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia

Acta Psychiatrica Scandinavica

Volumn 130, Issue 6, 2014, Pages 470-486

  Stubbs, B ^a   De Hert, M ^b   Sepehry, A A ^c   Correll, C U ^d   Mitchell, A J ^e   Soundy, A ^f   Detraux, J ^b   Vancampfort, D ^b,g  

^a UNIVERSITY OF GREENWICH   (United Kingdom)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^e LEICESTER GENERAL HOSPITAL   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

Author keywords

Antipsychotics; Bone mass; Bone mineral density; Hyperprolactinemia; Meta analysis; Osteopenia; Osteoporosis; Physical health; Schizophrenia; Screening

Indexed keywords

NEUROLEPTIC AGENT; OSTEOCALCIN; VITAMIN D;

AGE DISTRIBUTION; ARTICLE; ASIA; BODY MASS; BONE DENSITY; BONE MASS; COMPARATIVE STUDY; DISEASE DURATION; DRUG USE; EUROPE; HUMAN; HYPERPROLACTINEMIA; META ANALYSIS; NORTH AMERICA; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL ACTIVITY; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEX DIFFERENCE; SMOKING; SYSTEMATIC REVIEW; ADULT; AGE; BONE DISEASES, METABOLIC; FEMALE; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR; YOUNG ADULT;

ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; BONE DISEASES, METABOLIC; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTH AMERICA; OSTEOPOROSIS; PREVALENCE; REGRESSION ANALYSIS; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84909636869     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12313     Document Type: Article

References (64)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-650.
2. Kanis JA. Osteoporosis III: diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-1936.
3. Surgeons AAOO. Osteoporosis and bone health. Available at: http://www.aaos.org/news/aaosnow/may09/clinical8.asp [cited November 27, 2013].
4. Kanis J, McCloskey E, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57.
5. Halbreich U. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs 2007;21:641-657.
6. Crews MPK, Howes OD. Is antipsychotic treatment linked to low bone mineral density and osteoporosis? A review of the evidence and the clinical implications. Hum Psychopharmacol 2012;27:15-23.
7. Kishimoto T, De Hert M, Carlson HE, Manu P, Correll CU. Osteoporosis and fracture risk in people with schizophrenia. Curr Opin Psychiatry 2012;25:415-429.
8. Holt RIG. Osteoporosis in people with severe mental illness: a forgotten condition. Maturitas 2010;67:1-2.
9. Javaid MK, Holt RI. Understanding osteoporosis. J Psychopharmacol 2008;22:38-45.
10. Stubbs B. Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: considerations in relation to bone mineral density. J Psychiatr Ment Health Nurs 2009;16:838-842.
11. Law MR, Hackshaw AK. A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 1997;315:841-846.
12. Freeman TP, Stone JM, Orgaz B, Noronha LA, Minchin SL, Curran HV. Tobacco smoking in schizophrenia: investigating the role of incentive salience. Psychol Med 2013;1:1-9.
13. Vancampfort D, De Hert M, De Herdt A et al. Associations between perceived neighbourhood environmental attributes and self-reported sitting time in patients with schizophrenia: a pilot study. Psychiatry Res 2014;215:33-38.
14. Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr Scand 2012;125:352-362.
15. Crews M, Lally J, Gardner-Sood P et al. Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res 2013;150:533-537.
16. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014;28:421-453.
17. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129-134.
18. Sørensen HJ, Jensen SOW, Nielsen J. Schizophrenia, antipsychotics and risk of hip fracture: a population-based analysis. Eur Neuropsychopharmacol 2013;23:872-878.
19. Jalbert JJ, Eaton CB, Miller SC, Lapane KL. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010;11:120-127.
20. Wu H, Deng L, Zhao L, Zhao J, Li L, Chen J. Osteoporosis associated with antipsychotic treatment in schizophrenia. Int J Endocrinol 2013;2013:167138.
21. Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006;18:43-48.
22. Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000;283:2008-2012.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Clin Trials 2009;6:1-6.
24. World Health Organisation. WHO scientific group on the assessment of osteoporosis at primary health care level. WHO. Available at: http://www.who.int/chp/topics/Osteoporosis.pdf [cited December 1, 2013].
25. American Psychiatric Association. Diagnostic and statistical manual of mental disorders - DSM-IV-TR, 4th edn. Washington, DC: American Psychiatric Association, 2000.
26. World Health Organisation. The ICD-10 classification of mental and behavioural disorders - diagnostic criteria for research. Geneva: World Health Organisation, 1993.
27. Chin K-Y, Ima-Nirwana S. Calcaneal quantitative ultrasound as a determinant of bone health status: what properties of bone does it reflect? Int J Med Sci 2013;10:1778-1783.
28. Wells G, Shea B, O'Connell D, Peterson JEA. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp [cited 1 December 2013].
29. Hedges LV, Olkin L. Statistical models for meta-analysis. New York: Academic Press, 1985.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
31. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-1101.
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
33. Doknic M, Maric NP, Britvic D et al. Bone remodelling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. Neuroendocrinology 2011;94:246-254.
34. Howes O, Simpson L, Meaney A, O'Keane V, Murray R, Smith S. Are prolactin raising antipsychotics associated with osteoporosis? J Psychopharmacol 2002;16:23.
35. Hummer M, Malik P, Gasser RW et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005;162:162-167.
36. Jung D-U, Conley RR, Kelly DL et al. Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 2006;67:1391-1396.
37. Jung D-U, Kelly DL, Oh M-K et al. Bone mineral density and osteoporosis risk in older patients with schizophrenia. J Clin Psychopharmacol 2011;31:406-410.
38. Kinon BJ, Liu-Seifert H, Stauffer VL, Jacob J. Bone loss associated with hyperprolactinemia in patients with schizophrenia. Clin Schizophr Relat Psychoses 2013;7:115-123.
39. Kishimoto T, Watanabe K, Takeuchi H et al. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res 2005;77:113-115.
40. Kishimoto T, Watanabe K, Shimada N, Makita K, Yagi G, Kashima H. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 2008;69:385-391.
41. Lin C-H, Huang K-H, Chang Y-C et al. Clozapine protects bone mineral density in female patients with schizophrenia. Int J Neuropsychopharmacol 2012;15:897-906.
42. Lehman D, Meyer JM. Decreased bone mineral density in male schizophrenia patients. Schizophr Res 2005;76:131-133.
43. Liu-Seifert H, Kinon BJ, Ahl J, Lamberson S. Osteopenia associated with increased prolactin and aging in psychiatric patients treated with prolactin-elevating antipsychotics. Ann N Y Acad Sci 2004;1032:297-298.
44. Maric N, Popovic V, Jasovic-Gasic M, Pilipovic N, Van Os J. Cumulative exposure to estrogen and psychosis: a peak bone mass, case-control study in first-episode psychosis. Schizophr Res 2005;73:351-355.
45. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-508.
46. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005;25:26-31.
47. Ranjbar F, Farjamfar M, Aliasgarzadeh A, Alizadeh M. P03-110 - The evaluation of bone mineral density and osteoporosis in schizophrenic patients. Eur Psychiatry Supp 2010;25:1090.
48. Jenn-Huei R, Nan-Ping Y, Ching-Mo C, Chih-Yuan L, Tsuo-Hung L, Pesus C. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 2009;10:1-7.
49. Stubbs B, Zapata-Bravo E, Haw C. Screening for osteoporosis: a survey of older psychiatric inpatients at a tertiary referral centre. Int Psychogeriatr 2009;21:180-186.
50. Sugawara N, Yasui-Furukori N, Umeda T et al. Effect of age and disease on bone mass in Japanese patients with schizophrenia. Ann Gen Psychiatry 2012;11:5.
51. Van Der Leeuw C, Habets P, Domen P, Van Kroonenburgh M, Van Os J, Marcelis M. Bone mineral density as a marker of cumulative endogenous estrogen exposure: relationship to background genetic risk of psychotic disorder. Schizophr Res 2013;143:25-31.
52. Leucht S, Burkard T, Henderson J, Maj M, Sartorious N. Physical illness and schizophrenia: a review of the literature. Acta Psychiatr Scand 2007;116:317-333.
53. Vancampfort D, Probst M, Scheewe T, Knapen J, De Herdt A, De Hert M. The functional exercise capacity is correlated with global functioning in patients with schizophrenia. Acta Psychiatr Scand 2012;125:382-387.
54. Dipasquale S, Pariante CM, Dazzan P, Aguglia E, McGuire P, Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J Psychiatr Res 2013;47:197-207.
55. Calvo MS, Whiting SJ, Barton CN. Vitamin D fortification in the United States and Canada: current status and data needs. Am J Clin Nutr 2004;80(Suppl.):1710S-1716S.
56. Liu H, Paige NM, Goldzweig CL et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med 2008;148:685.
57. Babatunde OO, Forsyth JJ. Quantitative ultrasound and bone's response to exercise: a meta analysis. Bone 2013;53:311-318.
58. Bauer DC, Ewing SK, Cauley JA, Ensrud KE, Cummings SR, Orwoll ES. Quantitative ultrasound predicts hip and non-spine fracture in men: the MrOS study. Osteoporos Int 2007;18:771-777.
59. Partti K, Heliövaara M, Impivaara O et al. Skeletal status in psychotic disorders: a population-based study. Psychosom Med 2010;72:933-940.
60. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 2011;154:356-364.
61. National Osteoporosis S Society. Osteoporosis sources for primary care. Available at: http://www.osteoporosis-resources.org.uk/investigation/8-how-should-gps-use-bone-densitometry [cited 1 April 2014].
62. Lim LS, Hoeksema LJ, Sherin K. Screening for osteoporosis in the adult U.S. population: ACPM position statement on preventive practice. Am J Prev Med 2009;36:366-375.
63. Sherrington C, Whitney JC, Lord SR, Herbert RD, Cumming RG, Close JCT. Effective exercise for the prevention of falls: a systematic review and meta-analysis. J Am Geriatr Soc 2008;56:2234-2243.
64. Stubbs B, Probst M, Soundy A et al. International Organization of Physical Therapists in Mental Health. Physiotherapists can help implement physical activity programmes in clinical practice. Br J Psychiatry 2014;204:164.